Triple Negative Breast Cancer Drug Development Summit

Temi della conferenza
This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer.

Breast cancer (BC) is the most common solid tumor in women, with the triple negative subtype associated with poorer overall survival and a higher probability of cancer recurrence.

Professional congress organizer (PCO)
Hanson Wade

Annotazioni
Brochure: https://go.evvnt.com/729098-2?pid=4832

Speakers: Alison L. Hannah, Senior Vice President and Chief Medical Officer, CytomX Therapeutics, Angus Sinclair, VP Immuno-Oncology, IGM Biosciences, and more.

https://go.evvnt.com/729098-1?pid=4832

Mr. Customer Services